AstraZeneca Pharma India gains on regulator nod to import lung cancer drug
10/03/2025 07:52
** AstraZeneca Pharma India ASTR.NS rises 2.1% to 7,622.9 rupees, highest in about a month ** Biopharmaceutical co receives Indian drug regulator's permission to import Durvalumab solution for sale, distribution ** Drug is used to treat patients with a certain type of lung cancer ** Shares trading above 50-, 100-, 200-day moving avg ** ASTR up 2.2% YTD, after gaining 32% in 2024 (Reporting by Aleef Jahan in Bengaluru) ((aleefjahan.cs@thomsonreuters.com))
Recent news on Astrazeneca Pharma India
See all newsBrief: Astrazeneca Pharma Gets Permission To Import For Sale Of Trastuzumab Deruxtecan
India's Astrazeneca Pharma logs worst slide in two months on quarterly profit drop
Brief: Astrazeneca Pharma India March-Quarter PAT 448.8 Million Rupees
Brief: Astrazeneca Pharma India Recommends Dividend Of 36 Rupees Per Equity Share For Fy2025-26
Brief: Astrazeneca Pharma India Receives Permission To Import Durvalumab (Imfinzi) For Additional Indication